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Purpose
Insulin-like growth factors (IGF) regulate a wide range of biological functions including cell
proliferation, differentiation, and apoptosis through paracrine and autocrine mechanisms.
Accordingly, the present study analyzed polymorphisms of IGF genes and their impact on the
prognosis for patients with colorectal cancer.  
Materials and Methods
Four hundred and two consecutive patients with curatively resected colorectal adeno-
carcinoma were enrolled in the present study. The genomic DNA was extracted from fresh
colorectal tissue and 8 polymorphisms of IGF genes determined using a real-time polymerase
chain reaction genotyping assay.
Results
Pathologic stages after surgery were as follows: stage 0/I (n=85, 21.1%), stage II (n=147,
36.6%), stage III (n=145, 36.1%), and stage IV (n=25, 6.2%). Multivariate survival analysis including
stage, age, site of disease, and carcinoembryonic antigen level showed that the progression-
free survival for patients with the IGF2 +1280 GG genotype was slightly better than for the
patients with the combined IGF2 +1280 AA and AG genotype (p=0.056), although there was
no significant difference in the overall survival. However, the other polymorphisms were not
associated with survival.
Conclusion
None of the 8 IGF1 or IGF2 gene polymorphisms investigated in this study were found to be
independent prognostic markers for Korean patients with surgically resected colorectal
cancer. 
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Introduction
Anatomic and pathologic staging is still the most accurate predictor
of clinical outcomes in patients with colorectal cancer, enabling
physicians to evaluate the benefit of adjuvant chemotherapy for
individual patients. However, supplementing standard clinical and
pathologic staging with molecular markers would allow a more
precise identification of those patients with the highest or lowest risk
of relapse following colon cancer surgery. One of the most promising
molecular markers that have been investigated in relation to colorectal
cancer is the presence of tumor microsatellite instability [1].In addition to their classical role as endocrine hormones, insulin-
like growth factors (IGF) regulate a wide range of biological functions,
such as cell proliferation, differentiation, and apoptosis, through
paracrine and autocrine mechanisms [2]. Also, the IGF1 receptor-
mediated initiation of signal transduction activates important intra-
cellular signal pathways, including the Ras/Raf/mitogen-activated
protein kinase and phosphoinositide 3-kinase pathway [3]. IGF1 is a
polypeptide that has previously been associated with sporadic colo-
rectal cancer. Numerous in vitro and animal studies of colorectal
cancer have implicated IGF1 in cell transformation, tumor growth,
metastasis, and poor prognosis [4-7]. In addition, epidemiologic studies
have indicated that high plasma IGF1 plays a role in energy balance,
which has also been shown to influence risk for colorectal cancer [4,5]. 
Single nucleotide polymorphisms (SNPs) have already been widely
implicated in cancer development, prognosis, and treatment response,
yet similar evidence is lacking for IGF genes. Although IGF1tag SNPs
have been associated with circulating IGF1 levels [8], functional poly-
morphisms that may be mediating these associations have not been
identified. A cytosine-adenosine dinucleotide repeat sequence (CA)
that resides in the promoter region has been inconsistently associated
with serum levels and with risk of colorectal cancer. However, a
recent study by Wong et al. [9] reported that a putative regulatory
IGF1 in the promoter region is associated with reduced colorectal
cancer risk. Furthermore, Zecevic et al. [10] also demonstrated that
IGF1 variant genotypes modify risk of a hereditary nonpolyposis
colorectal cancer. For pancreatic cancer, IGF1 haplotype and the
IGF2 Ex4 -233 CĥT polymorphism was also found to be signi-
ficantly associated with risk of pancreatic cancer [11]. Therefore,
given these results, it is possible that SNPs in the IGF genes may
play an important role in cancer development and prognosis. 
However, no published study has yet investigated SNPs in IGF
genes and their relationship to the clinical outcomes of colorectal
cancer. Hence, the present study analyzed 8 SNPs of IGF genes and
their impact on prognosis for patients with colorectal cancer.
Materials and Methods
1   Study population
All the tissues investigated in this study were obtained from 402
consecutive Korean patients who had undergone a surgical resection
between January, 2003 and August, 2006 at Kyungpook National
University Hospital (Daegu, Korea). Written informed consent for gene
expression analyses was received from all the patients before surgery,
and the study approved by the Institutional Research Board at Kyung-
pook National University Hospital. The diagnosis and staging of the
colorectal cancer was assessed according to the World Health Organi-
zation (WHO) classifications [12] and tumor, node and metastasis
(TNM) classifications set out by the American Joint Committee on
Cancer [13].
2  SNP selection
Due to the huge number of SNPs in the human genome, the efficient
selection of the SNPs most likely to contribute to phenotypic effects
was the first challenge. Thus, a prioritizing strategy was created using
public databases that provide diverse information on the potential
phenotypic risks of SNPs. Finally, 8 potential functional
polymorphisms from the 3’-untranslated region (UTR) and the intron
regions were identified (IGF1 -16540 AĥG, IGF1 +1830 CĥT, IGF1
-177 GĥC, IGF1 -533 CĥT, IGF1 -2995 CĥA, IGF2 +1280 AĥG,
IGF2 -69 CĥT, IGF2 -233 CĥT) (Table 1). 
3  Genotyping of polymorphisms in IGF genes
Genomic DNA was extracted from fresh colorectal mucosal tissue
at the time of surgery using the Wizard genomic DNA purification kit
(Promega, Madison, WI). The 8 selected polymorphisms of the IGF
genes were then determined using a real-time polymerase chain reaction
(PCR) genotyping assay. For quality control, genotyping analysis was
performed blind. The selected PCR-amplified DNA samples (n=2, for
each genotype) were also examined by DNA sequencing to confirm
the genotyping results.
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Gene Chromosome SNP Location Reference No.
IGF1 12q22-q23 IVS2 -16540 AĥG Intron 2,288,378
Ex4 +1830 CĥT3 '-UTR 6,220
Ex4 -177 GĥC3 '-UTR 5,742,714
-533 CĥT Promoter 5,742,612
-2995 CĥA Promoter 12,579,108
IGF2 11p15.5 IVS1 +1280 AĥG Intron 3,213,216
IVS2 -69 CĥT Intron 3,213,232
Ex4 -233 CĥT3 '-UTR 2,230,949
Table 1. Characteristics of examined SNPs
SNP, single nucleotide polymorphism; IGF, insulin-like growth factors; 3’-UTR, 3’-untranslated region.Yoon Young Cho, et al_IGF Gene SNPs and Survival of Colorectal Cancer
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4 Statistical analysis
The genotypes for each SNP were analyzed as a three-group
categorical variable (referent model), and also grouped according to
the dominant and recessive model. The survival estimates were
calculated using the Kaplan-Meier method. The differences in
overall survival (OS), disease specific survival (DSS) or progression-
free survival (PFS) according to the SNPs in the IGF genes were
compared using log-rank tests. Cox’s proportional hazard regression
model was used for the multivariate survival analyses, and the
analyses were always adjusted for age (< 60 years vs.60 years),
site of disease (colon vs. rectum), preoperative carcinoembryonic
antigen (CEA) level (normal vs. elevated), and stage (0 to IV). The
hazard ratio (HR) and 95% confidence interval (CI) were also
estimated. A cut-off p-value of 0.05 was adopted for all the statistical
analyses. The statistical data was obtained using an SPSS ver. 11.5
(SPSS Inc., Chicago, IL) or SAS Genetic software (SAS Institute,
Cary, NC). 
Results
1   Patient characteristics and survival analysis
The median age of the patients was 64 years (range, 21 to 85 years),
and 217 (54.0%) patients were male. Two hundred and twenty-one
(55.0%) patients had colon cancer, whereas the others had rectal
cancer. The pathologic stages after surgical resection were as follows:
stage 0/I (n=85, 21.1%), stage II (n=147, 36.6%), stage III (n=145,
36.1%), and stage IV (n=25, 6.2%). Among the 291 patients with
stage II or III diseases, 268 (92.1%) patients received adjuvant
chemotherapy with 6 cycles of 5-fluorouracil/leucovorin±radio-
therapy (n=76), 12 cycles of 5-FU/LV+oxaliplatin (FOLFOX) (n=11),
8 cycles of capecitabine (n=9), or doxifluridine for 1 year (n=171)
(Table 2). At the time of last analysis, 85 patients had experienced a
disease relapse and 72 patients had died. However, the deaths of 11
patients were not related to colorectal cancer. At the median follow-
up duration of 37.0 months (range, 0.7 to 65.7 months), the
estimated 5-year OS and PFS for all the patients was 70.9±3.7% and
74.4±3.0%, respectively, and the survival rate differed according to
the disease stage (pģ0.001) (Fig. 1).
2  Genotype frequency and effects on survival
The 8 SNPs of the IGF genes were successfully amplified in
more than 95% of the patients. The IGF2 -69CĥT and IGF2 -
233CĥT SNPs were excluded from analysis because their minor
allele frequencies were less than 5%. The frequencies of each
genotype also conformed to a Hardy-Weinberg equilibrium (pĥ0.05).
There were no sexual differences in relation to any genotype and
allele. No correlation was observed between any frequency of the
genotype or allele and the T, N, or M stage. In a univariate analysis,
Characteristics Total (n=402)
Median age (range, yr) 64 (21-85)
Gender
Male 217 (54.0)
Female 185 (46.0)
Primary site
Colon 221 (55.0)
Rectum 181 (45.0)
Histological differentiation
Well 84 (20.9)
Moderate 302 (75.1)
Poor or signet ring 16 (4.0)
CEA, elevated  81 (20.2)
Surgery
Open 112 (27.9)
Laparoscopy 290  (72.1)
Pathologic stage
0/I 85 (21.1)
II 147 (36.6)
III 145 (36.1)
IV 25 (6.2)
Adjuvant chemotherapy (n=268)
5-fluorouracil/leucovorin±radiotherapy 76 (28.3)
FOLFOX-4 11 (4.1)
Capecitabine 9 (3.4)
Doxifluridine 172 (64.2)
Relapse 85 (21.1)
Death 72 (17.9)
Values are presented as number (%). CEA, carcinoembryonic antigen; FOLFOX,
5-FU/LV+oxaliplatin.
Table 2. Patient characteristics
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Fig. 1. Progression-free survival curves for all patients according to
stage (pģ0.001).Cancer Res Treat. 2011;43(3):189-194
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PFS or OS was not different according to the SNPs of the IGF genes
(Table 3). Multivariate survival analysis including stage, age, site of
disease, and CEA level showed that PFS for patients with the IGF2
+1280 GG genotype was slightly better than for patients with
combined IGF2 +1280 AA and AG genotype (HR, 0.614; 95% CI,
0.366 to 1.011; p=0.056), although there was no significant diffe-
rence in the DSS or OS. However, the other polymorphisms were
not associated with survival. 
In haplotype analysis for IGF1 or IGF2 gene, none of haplotypes
associated with prognosis of colorectal cancer. For the clinicopathologic
parameters, the age, CEA level, and TNM stage were all significant
prognostic factors in a Cox model for PFS or DSS (Tables 4 and 5).
Discussion
The prognostic impact of 8 SNPs of IGF genes was investigated
in a large population of patients with surgically resected colorectal
adenocarcinoma. However, no association was observed between
the polymorphisms in the IGF1 or IGF2 genes and survival in these
patients. Given the homogenous ethnic background of Korean pa-
tients, any potential confounding effect due to ethnicity is likely to
be small in the present study.
Since extensive studies, both in vitro and in vivo, have suggested
that IGF promotes cancer growth, prevent apoptosis, and increase
metastasis [14-16], it is possible that germ line polymorphisms in
IGF genes might alter serum IGF levels, thereby affecting an
individual’s cancer risk or prognosis. In previous studies, polymorphic
variants of IGF1 and elevated serum levels of IGF1 protein have
been associated with an increased risk of common cancers including
prostate, colorectal, and breast cancers [8,9,17-19], while infor-
mation on IGF2 polymorphisms and their correlation with cancer
risk or prognosis is scarce, and the results that have been published
are similarly inconsistent [20,21]. For example, significant associations
between the SNPs in the IGF1 promoter region (IGF1 -2995 GĥA)
and the risk of cancer were found in 298 Chinese patients with
colorectal cancer and 1,142 controls [9], suggesting that IGF1 plays
a role in colonic carcinogenesis and genetically inherited variation in
IGF1 expression influences risk of colorectal cancer. Tsuchiya et al.
[22] also reported that IGF1 (CA) repeat polymorphism in the
promoter region was associated with prognosis in 111 prostate
cancer patients with bone metastasis at the diagnosis. However,
these polymorphisms were not found to have any prognostic signi-
ficance in the survival of the patients with colorectal cancer in the
current study. Furthermore, Patel et al. [23] have demonstrated that
several genetic variations in IGF1 and IGF binding protein 3 (IGFBP3)
predicts circulating levels of IGF1 and IGFBP3, respectively, but no
associations between these variations and breast cancer risk. It is
thus unlikely that these polymorphisms and their associated hor-
mone levels substantially affect breast cancer risk. 
The present study also evaluated SNPs of IGF2 gene, yet none
was found to have a significant influence on the prognosis of co-
lorectal cancer. In a previous study by Suzuki et al. [11] that compared
the frequency of 6 SNPs of IGF1 and IGF2 in a large-scale case
control study to determine whether genetic variations of IGF modify
pancreatic cancer risk, the IGF2 3'-UTR Ex4 -233T/T genotype was
significantly associated with a reduced risk of pancreatic cancer. In
contrast, Lai et al. [20] reported that the polymorphism of IGF2 gene
is not likely to contribute to the pathogenesis of prostate cancer or be
involved in tumor progression, although the expression of IGF2 and
androgen receptors in the prostate suggested that IGF2 plays a role in
regulating androgen receptor expression in prostate cancer cells.
Thus, given these results, a better understanding of the distinct
polymorphisms in IGF genes and protein expression regulation in
different cancers will be a critical step toward the clinical utilization
of this new subclass of genetic variations in cancer management.
Conclusion
None of the 8 SNPs of the IGF genes investigated in this study
was found to be an independent prognostic marker for Korean
Table 3. Genotype frequencies and univariate survival analysis
SNPs
Frequency Progression-free Overall survival
(%) survival (p-value) (p-value)
IVS2 -16540 AĥG n=402 NS NS
A/A 10 (2.5)
A/G 275 (68.4)
G/G 117 (29.1)
Ex4 +1830 CĥT n=393 NS NS
C/C 65 (16.5)
C/T 188 (47.8)
T/T 140 (35.6)
Ex4 -177 GĥC n=399 NS NS
G/G 272 (68.1)
G/C 116 (29.1)
C/C 11 (2.8)
-533 CĥT n=402 NS NS
C/C 36 (9.0)
C/T 142 (35.3)
T/T 224 (55.7)
-2995 CĥA n=401 NS NS
C/C 227 (56.6)
C/A 138 (34.4)
A/A 36 (9.0)
IVS1 +1280 AĥG n=402 NS NS
A/A 50 (12.4)
A/G 181 (45.1)
G/G 171 (42.5)
SNP, single nucleotide polymorphism; NS, not significant.Yoon Young Cho, et al_IGF Gene SNPs and Survival of Colorectal Cancer
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SNPs Frequency (%)
Age (yr)
a) CEA level
a) Pathologic stage
a)
60 ģ60 Elevated Normal 0/I II III IV
IVS2 -16540 AĥG n=402
A/A 10 (2.5) 8 (80.0) 2 (20.0) 1 (10.0) 9 (90.0) 4 (40.0) 3 (30.0) 3 (30.0) 0 (0)
A/G 275 (68.4) 175 (63.6) 100 (36.4) 60 (22.1) 211 (77.9) 57 (20.7) 103 (37.5) 98 (35.6) 17 (6.2)
G/G 117 (29.1) 62 (53.0) 55 (47.0) 20 (17.2) 96 (82.8) 24 (20.5) 41 (35.0) 44 (37.6) 8 (6.8)
Ex4 +1830 CĥT n=393
C/C 65 (16.5) 40 (61.5) 25 (38.5) 11 (17.2) 53 (82.8) 12 (18.5) 25 (38.5) 24 (36.9) 4 (6.2)
C/T 188 (47.8) 109 (58.0) 79 (42.0) 32 (17.2) 154 (82.8) 42 (22.3) 75 (39.9) 60 (31.9) 11 (5.9)
T/T 140 (35.6) 90 (64.3) 50 (35.7) 36 (26.1) 102 (73.9) 30 (21.4) 45 (32.1) 55 (39.3) 10 (7.1)
Ex4 -177 GĥC n=399
G/G 272 (68.1) 172 (63.2) 100 (36.8) 60 (22.4) 208 (77.6) 57 (21.0) 102 (37.5) 96 (35.3) 17 (6.3)
G/C 116 (29.1) 63 (54.3) 53 (45.7) 19 (16.5) 96 (83.5) 23 (19.8) 43 (37.1) 42 (36.2) 8 (6.9)
C/C 11 (2.8) 7 (63.6) 4 (36.4) 1 (9.1) 10 (90.9) 5 (45.5) 2 (18.2) 4 (36.4) 0 (0)  
-533 CĥT n=402
C/C 36 (9.0) 24 (66.7) 12 (33.3) 9 (25.0) 27 (75.0) 9 (25.0) 13 (36.1) 13 (36.1) 1 (2.8)
C/T 142 (35.3) 81 (57.0) 61 (43.0) 26 (18.6) 114 (81.4) 24 (16.9) 60 (42.3) 49 (34.5) 9 (6.3)
T/T 224 (55.7) 140 (62.5) 84 (37.5) 46 (20.8) 175 (79.2) 52 (23.2) 74 (33.0) 83 (37.1) 15 (6.7)
-2995 CĥA n=401
C/C 227 (56.6) 142 (62.6) 85 (37.4) 47 (20.9) 178 (79.1) 53 (23.3) 76 (33.5) 84 (37.0) 14 (6.2)
C/A 138 (34.4) 78 (56.5) 60 (43.5) 25 (18.4) 111 (81.6) 23 (16.7) 58 (42.0) 48 (34.8) 9 (6.5)
A/A 36 (9.0) 24 (66.7) 12 (33.3) 9 (25.0)  27 (75.0) 9 (25.0) 13 (36.1) 13 (36.1) 1 (2.8)
IVS1 +1280 AĥG n=402
A/A 50 (12.4) 35 (70.0) 15 (30.0) 11 (22.4) 38 (77.6) 13 (26.0) 16 (32.0) 19 (38.0) 2 (4.0)
A/G 181 (45.1) 115 (63.5) 66 (36.5) 34 (18.9) 146 (81.1) 36 (19.9) 79 (42.0) 61 (33.7) 8 (4.4)
G/G 171 (42.5) 95 (55.6) 76 (44.4) 36 (21.4) 132 (78.6) 36 (21.1) 55 (32.2) 65 (38.0) 15 (8.8)
Table 4. Genotype frequencies and clinicopathologic characteristics
SNP, single nucleotide polymorphism; CEA, carcinoembryonic antigen. 
a)p-value, not significant.
Characteristics Progression-free survival Disease-specific survival
HR 95% CI p-value HR 95% CI p-value
Age (yr) 0.028 0.011
ģ60 1 1
60 1.718 1.165-2.535 2.254 1.209-4.204
Site of disease 0.852 0.315
Colon 1 1
Rectum 1.112 0.768-1.612 1.570 0.877-2.809
Stage ģ0.001 ģ0.001
0/I 1 1
II 2.652 0.761-9.239 4.498 0.553-36.583
III 11.646 3.303-37.644 25.106 3.387-186.085
IV 64.018 19.250-212.903 52.377 19.250
CEA level ģ0.001 0.002
Normal 1 1
Elevated 1.827 1.248-2.674 2.496 1.395-4.464
IGF2 +1280AĥG 0.056 0.295
A/A+A/G 1 1
G/G 0.614 0.366-1.011 0.730 0.406-1.315
Table 5. Multivariate survival analysis 
p-values correspond to multivariate Cox model adjusted for age, site of disease, CEA level, and stage. HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen;
IGF2, insulin-like growth factors 2. patients with surgically resected colorectal cancer. However, since
genetic polymorphisms often vary between different ethnic groups,
further studies are warranted to clarify the association between IGF1
or IGF2 gene polymorphisms and the prognosis of colorectal cancer
in diverse ethnic populations.
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